Table 6.
The recovery of AKI in 214 patients infected by SARS-CoV and 66 patients infected by SARS-CoV-2 from the date of initial AKI event
| Creatinine Level | SARS-CoV | |||||
|---|---|---|---|---|---|---|
| At d 0 (n=214) | At d 7 (n=139) | At d 30 (n=85) | At d 90 (n=70) | P valuea,b | P valuec | |
| Median (IQR) | 140 (114–196) | 99 (68–191) | 75 (57–108) | 75 (63–103) | <0.001a | |
| No AKI/AKD/CKD, n (%) | 0 (0) | 94 (67.6) | 67 (77.9) | 58 (82.9) | <0.001b | 0.17c |
| AKI stage 1, n (%) | 177 (82.7) | 19 (13.7) | AKD 19 (22.1) | CKD 12 (17.1) | ||
| AKI stage 2, n (%) | 17 (7.9) | 3 (2.2) | ||||
| AKI stage 3, n (%) | 20 (9.3) | 23 (16.5) | ||||
| Creatinine Level | SARS-CoV-2 | |||||
| At d 0 (n=66) | At d 7 (n=65) | At d 30 (n=63) | At d 90 (n=63) | P valuea,b | P valuec | |
| Median (IQR) | 108 (91–129) | 83 (69–103) | 75 (67–97) | 75 (66–94) | <0.001a | |
| No AKI/AKD/CKD, n (%) | 0 (0) | 55 (84.6) | 55 (87.3) | 58 (92.1) | <0.001b | 0.20c |
| AKI stage 1, n (%) | 63 (95.5) | 3 (4.6) | AKD 8 (12.7) | CKD 5 (7.9) | ||
| AKI stage 2, n (%) | 3 (4.5) | 1 (1.5) | ||||
| AKI stage 3, n (%) | 0 (0) | 6 (9.2) | ||||
| P value | 0.009d | 0.005c | ||||
a
Friedman test was used to compare creatinine level at d 0, 7, 30, and 90.
b
Bhapkar test was used compare creatinine level and AKI status at d 0 and 7.
c
Generalized estimating equations was used to compare presence of any AKI/AKD at d 7, 30, and 90.
d
Categories of AKI/AKD between SARS-CoV and SARS-CoV-2 were compared by chi-squared test or Fisher’s exact test, as appropriate.